Latest filings (excl ownership)
8-K
Other Events
9 Aug 24
S-8
Registration of securities for employees
8 Aug 24
S-8
Registration of securities for employees
8 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
8 Aug 24
8-K
Other Events
28 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
11 Jun 24
8-K
Other Events
3 Jun 24
8-K
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
23 May 24
DEFA14A
Additional proxy soliciting materials
17 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Iovance Biotherapeutics Reports First Quarter 2024
9 May 24
ARS
2023 FY
Annual report to shareholders
1 May 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Other Events
3 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
8-K
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
4 Mar 24
8-K
Other Events
29 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023
28 Feb 24
8-K
Other Events
22 Feb 24
424B5
Prospectus supplement for primary offering
21 Feb 24
8-K
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
20 Feb 24
8-K
Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval
20 Feb 24
8-K
Other Events
26 Jan 24
8-K
Other Events
8 Jan 24
8-K
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
27 Dec 23
UPLOAD
Letter from SEC
21 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023
7 Nov 23
UPLOAD
Letter from SEC
26 Oct 23
8-K
U.S. Food and Drug Administration Updates
15 Sep 23
8-K
Regulation FD Disclosure
18 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Iovance Biotherapeutics Reports Second Quarter and First Half 2023
8 Aug 23
8-K
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
13 Jul 23
424B5
Prospectus supplement for primary offering
11 Jul 23
8-K
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
11 Jul 23
Latest ownership filings
SC 13G/A
STATE STREET CORP
18 Oct 24
4
Frederick G Vogt
16 Oct 24
4
FINCKENSTEIN FRIEDRICH GRAF
16 Oct 24
4
IGOR BILINSKY
16 Oct 24
4
Frederick G Vogt
5 Sep 24
4
FINCKENSTEIN FRIEDRICH GRAF
5 Sep 24
4
IGOR BILINSKY
5 Sep 24
4
Jean-Marc Bellemin
5 Sep 24
4
Frederick G Vogt
17 Jul 24
4
FINCKENSTEIN FRIEDRICH GRAF
17 Jul 24
4
IGOR BILINSKY
17 Jul 24
4
Athena Countouriotis
13 Jun 24
4
WENDY L YARNO
13 Jun 24
4
MICHAEL WEISER
13 Jun 24
4
Ryan D Maynard
13 Jun 24
4
Iain D. Dukes
13 Jun 24
4
FINCKENSTEIN FRIEDRICH GRAF
5 Jun 24
4
IGOR BILINSKY
5 Jun 24
4
Frederick G Vogt
5 Jun 24
4
Frederick G Vogt
17 Apr 24
4
FINCKENSTEIN FRIEDRICH GRAF
17 Apr 24
4
IGOR BILINSKY
17 Apr 24
SC 13D/A
Quogue Capital LLC
19 Mar 24
4
FINCKENSTEIN FRIEDRICH GRAF
6 Mar 24
4
Frederick G Vogt
6 Mar 24
4
IGOR BILINSKY
6 Mar 24
4
WENDY L YARNO
5 Mar 24
4
Wayne P. Rothbaum
5 Mar 24
4
Frederick G Vogt
5 Mar 24
4
Ryan D Maynard
5 Mar 24
4
MICHAEL WEISER
5 Mar 24
4
MERRILL A MCPEAK
5 Mar 24
4
Iain D. Dukes
5 Mar 24
4
FINCKENSTEIN FRIEDRICH GRAF
5 Mar 24
4
IGOR BILINSKY
5 Mar 24
4
Jean-Marc Bellemin
5 Mar 24
4
Athena Countouriotis
5 Mar 24
SC 13G
PERCEPTIVE ADVISORS LLC
1 Mar 24
4
MERRILL A MCPEAK
20 Feb 24
4
Iain D. Dukes
20 Feb 24